R&D for avidin in targeting therapies


 Designing stable artificial receptors in diseased tissues for targeting of biotinylated therapeutics: Treatment of un-resectable somatostatin-receptor (SSTR) positive tumors is difficult (chemotherapy and radiotherapy often fail). Oxidized oligosaccharide-derived avidins with unaffected oxidation-sensitive biotin-binding capacity (Trp) have demonstrated enhanced specific diseased tissue binding properties, with reported clearance increased from ~2 hrs (AVI) to ~2 wks (AVIox), therefore allowing for tissue pre-targeted radionuclide imaging (111I-biotinDOTA (Indium-111) scintigraphy) & therapy (90Y-biotinDOTA (Yttrium-90) b-emitting).

Reference AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. De Santis R1, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M, Carminati P.)

The e-Proteins R&D team develops a similar formulation for standardizing AVIox to include silencing of potentially allergenic epitopes, thus facilitating the parenteral approach of avidin-based biotinylated radionuclide therapeutics

Avidin targeting 3T3 avidin targeting PC3


Ce site utilise des cookies tiers destinés aux statistiques de fréquentation. En acceptant vous nous permettez de mieux vous connaitre et améliorer votre expérience sur notre site.

Accepter Décliner En savoir plus